First line and second line drug therapy
Three questions and a subtype the brief never names out loud. Establish IBS-D from the presentation before you prescribe, and deal with the cholecystectomy sitting in her history as a rival explanation.
Editorial process
Last reviewed · August 23, 2026
Which IBS is Jordan's, and why it decides the drug
The brief hands you a diagnosis and expects you to notice which kind. Diarrhoea-predominant IBS is the subtype here, and saying so is the move that makes the rest of the post coherent, because the first-line agents for IBS-D, IBS-C and the mixed subtype barely overlap. The features that justify the label are all in the vignette: pain relieved by defecation is a Rome criterion, and the absence of blood, of vomiting and of weight loss removes the alarm features that would send you looking for inflammatory bowel disease or malignancy instead. Say that you checked for alarm features and found none. IBS is a positive diagnosis made on symptom criteria, not a label applied once everything else is excluded, and a post that treats it as a diagnosis of exclusion has the modern framing backwards. Naming the criteria set you applied is worth a sentence, because it shows the diagnosis was reached rather than inherited.
The recent cholecystectomy is the detail that separates a careful post from a competent one. Post-cholecystectomy diarrhoea from bile acid malabsorption is common, presents almost exactly as this does, and responds to bile acid sequestrants rather than to anything on the standard IBS ladder. You are not being asked to overturn the given diagnosis, but naming the alternative and saying how you would tell them apart is exactly the clinical reasoning the assessor is hunting for. Then answer the three questions in the order asked. Keep the epidemiology paragraph specific with prevalence, the female predominance and the age distribution rather than calling IBS common. Write treatment goals as measurable targets for Jordan, not as aspirations. And when you reach therapy, give doses, mechanisms and monitoring, since the prompt asks for pharmacotherapeutic information and that is what the phrase means. Give the mechanism, the dose range and the monitoring parameter for every agent you name.
Likely learning objectives
- Classify an IBS presentation into a subtype before selecting therapy.
- Apply symptom-based criteria and alarm-feature screening as a positive diagnosis.
- Recognise post-cholecystectomy bile acid diarrhoea as a competing explanation.
- Present first-line and second-line agents with doses, mechanisms and monitoring.
Assignment instructions
Read the full question
Review every instruction before using the planning guidance that follows.
Jordan is a 35-year-old woman who presents with intermittent diarrhea with cramping that is relieved by defecation. The diarrhea is not bloody or accompanied by nausea and vomiting. Review of past medical history includes some childhood “stomach issues”, HTN, and a recent cholecystectomy. She works in the environmental department of a large hotel. . She denies alcohol and cigarette. Diagnosis: Irritable Bowel Syndrome (IBS): Please address the following questions in APA format: I. Discuss the epidemiology of IBS? II. What is your treatment goals for this patient? III. Discuss First line and second line drug therapy for IBS. Please include pharmacotherapeutic information. ***A minimum of 6 paragraphs is required for all posts. Support all posts with at least 2 cited peer review references within 5 years of publication (references cannot be older than 5 years).All posts are to be written in APA 6th edition format as required by the university.
Course-wide instructions that accompany this question
You must proofread your paper. But do not strictly rely on your computer’s spell-checker and grammar-checker; failure to do so indicates a lack of effort on your part and you can expect your grade to suffer accordingly. Papers with numerous misspelled words and grammatical mistakes will be penalized. Read over your paper – in silence and then aloud – before handing it in and make corrections as necessary. Often it is advantageous to have a friend proofread your paper for obvious errors. Handwritten corrections are preferable to uncorrected mistakes. Use a standard 10 to 12 point (10 to 12 characters per inch) typeface. Smaller or compressed type and papers with small margins or single-spacing are hard to read. It is better to let your essay run over the recommended number of pages than to try to compress it into fewer pages. Likewise, large type, large margins, large indentations, triple-spacing, increased leading (space between lines), increased kerning (space between letters), and any other such attempts at “padding” to increase the length of a paper are unacceptable, wasteful of trees, and will not fool your professor. The paper must be neatly formatted, double-spaced with a one-inch margin on the top, bottom, and sides of each page. When submitting hard copy, be sure to use white paper and print out using dark ink. If it is hard to read your essay, it will also be hard to follow your argument.
What this IBS discussion post must contain
- 01A discussion of the epidemiology of IBS.
- 02Stated treatment goals for this patient.
- 03First-line and second-line drug therapy for IBS with pharmacotherapeutic information.
- 04A minimum of six paragraphs.
- 05At least two cited peer-reviewed references published within the last five years.
Epidemiology, goals, then the two therapy lines
Establishing the subtype
Name IBS-D and cite the presenting features that support it.
What the assessor is likely looking for
Subtype argued from the vignette, not assumed.
Epidemiology with numbers
Give prevalence, sex distribution and typical age of onset.
What the assessor is likely looking for
Figures with a source rather than a claim that IBS is common.
The competing explanation
Raise bile acid diarrhoea after cholecystectomy and say how you would distinguish it.
What the assessor is likely looking for
A differential named and a discriminating test or trial proposed.
Treatment goals for Jordan
State targets in terms of stool frequency, pain days and function.
What the assessor is likely looking for
Goals stated as measurable endpoints for this patient.
First-line therapy
Cover dietary modification and the first-line agents with doses and mechanisms.
What the assessor is likely looking for
Pharmacotherapeutic detail, including what would be monitored.
Second-line therapy
Set out what follows if first-line fails, including the trial evidence behind it.
What the assessor is likely looking for
An escalation rule, not just a longer drug list.
Where current IBS pharmacotherapy is documented
Recommended databases
- NCBI Bookshelf (StatPearls)
- PubMed Central
- American College of Gastroenterology
- CINAHL
Search sequence
- 1.Read the IBS overview for subtype criteria before choosing any agent.
- 2.Search IBS-D pharmacotherapy restricted to the last five years, as the brief requires.
- 3.Look up rifaximin trial evidence rather than citing a textbook mention of it.
- 4.Check bile acid malabsorption after cholecystectomy to support the differential.
Reference shortlist
These are authoritative starting points, not a ready-made bibliography. A qualified reviewer must confirm that each source fits the assignment and supports the claim beside which it is cited.
Irritable Bowel Syndrome
StatPearls, NCBI Bookshelf · 2023
IBS subtypes, diagnostic criteria and the alarm features that must be absent.
Rifaximin
StatPearls, NCBI Bookshelf · 2024
Rifaximin pharmacology and dosing, for the second-line section's mechanism detail.
Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials
American Journal of Gastroenterology · 2016
Pooled trial evidence for rifaximin in IBS, so the escalation is argued from data.
Irritable Bowel Syndrome
MedlinePlus, U.S. National Library of Medicine · 2024
A patient-level summary, useful for framing the education part of the treatment goals.
Treatment for Irritable Bowel Syndrome
National Institute of Diabetes and Digestive and Kidney Diseases · 2024
The NIDDK treatment summary, for the dietary and first-line measures that precede drugs.
Before you post the IBS discussion
Common mistakes
- Never naming the subtype, then recommending agents for the wrong one.
- Presenting IBS as a diagnosis of exclusion rather than a positive symptom diagnosis.
- Ignoring the cholecystectomy and the bile acid diarrhoea it raises.
- Writing treatment goals as 'improve symptoms' with nothing measurable attached.
- Naming drug classes without doses, mechanisms or monitoring parameters.
Submission checklist
- Have you stated the subtype and the features that justify it?
- Did you say explicitly that alarm features were absent?
- Is post-cholecystectomy diarrhoea addressed as a differential?
- Do your treatment goals contain something you could measure?
- Are all references peer-reviewed and within five years?
Use this guide to plan and review your own work. Follow your institution's rules and read Brinevia's academic-integrity policy.
Written by
Maren Caldwell
MSN, RN, CNE
Medical-surgical nursing, pharmacology and NCLEX preparation
Maren is a registered nurse with over 15 years of clinical and educational experience in medical-surgical nursing. She writes on NCLEX preparation, patient care fundamentals, pharmacology and evidence-based practice.
Reviewed by
Dr. Tessa Redmond
DNP, RN, CNE
Evidence-based practice and clinical education
Tessa is a doctorally-prepared nurse educator. She reviews Brinevia content for clinical accuracy and alignment with current evidence-based guidelines.